Neuland Laboratories Limited (NEULANDLAB) Revenue 2023–2026

Name: Neuland Laboratories Limited (NEULANDLAB) revenue history 2023-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

Neuland Laboratories Limited annual revenue for fiscal 2026 was ₹19.3 billion, an increase of 34.7% from ₹14.3 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

NEULANDLAB Annual Revenue

Revenue (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Total Revenue	₹19.3B	₹14.3B	₹15.2B	₹11.6B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NEULANDLAB Quarterly Revenue

Revenue (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Total Revenue	₹6.4B	₹7.8B	₹4.4B	₹5.1B	₹2.9B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Revenue at Comparable Companies

AJANTPHARM Revenue — Ajanta Pharma Limited
EMCURE Revenue — Emcure Pharmaceuticals Limited
WOCKPHARMA Revenue — Wockhardt Limited
1276 Revenue — Jiangsu Hengrui Pharmaceuticals Co.,Ltd
4540 Revenue — Tsumura & Co.
PPLPHARMA Revenue — Piramal Pharma Limited

More NEULANDLAB metrics: Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow

All NEULANDLAB financial statements → Interactive NEULANDLAB charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.